6 articles | last updated: May 16 20:06:28
Patients experienced an average weight reduction of 18.8% over 24 weeks, positioning Roche as a strong contender in the competitive weight loss market.
- All patients treated with CT-388 lost at least 5% of their weight, with 45% losing over 20%.
- The drug mimics gut hormones GLP-1 and GIP to suppress appetite and control blood sugar.
- Mild to moderate gastrointestinal side effects were the most common adverse events reported.
- Roche's stock rose by 4% following the announcement of the trial results.
- The company aims to develop CT-388 for both obesity and type 2 diabetes treatment.
People, Places and Things In This Story
- Roche Holding AG Pharmaceutical company
- Glucagon-like peptide-1 receptor agonist Class of drugs
Categories:
- Business
- Healthcare
- Health
- Finance
- Geography
- Science
- Society
- Media